Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial
Year: 2022
Type: conference-abstract
Source: Cancer Research
Authors: Michael Gnant, Amylou C Dueck, Sophie Frantal, Miguel Martin, Hal Burstein, Richard Greil, Peter Fox, Antonio C Wolff, Arlene Chan, Eric Winer, Christian Singer, Kathy Miller, Marco Colleoni, Michelle Naughton, Gabor Rubovszky, Judith Bliss, Ingrid A Mayer, Guenther G Steger, Zbigniew Nowecki, Olwen Hahn, Norman Wolmark, Hope Rugo, Georg Pfeiler, Hannes Fohler, Otto Metzger, Céline Schurmans, Kathy P Theall, Dongrui R Lu, Kathleen Tenner, Christian Fesl, Angela DeMichele, Erica L Mayer, *shared last authorship
Institutions: Medical University of Vienna, Mayo Clinic, Austrian Breast & Colorectal Cancer Study Group, Hospital General Universitario Gregorio Marañón, Dana-Farber Cancer Institute, Paracelsus Medical University, Labor für Immunologische und Molekulare Krebsforschung, Government of New South Wales, Western NSW Local Health District, Johns Hopkins University, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, European Institute of Oncology, The Ohio State University, National Institute of Oncology, Institute of Cancer Research, Vanderbilt University, The Maria Sklodowska-Curie National Research Institute of Oncology, University of Chicago, University of Pittsburgh, NRG Oncology, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Pfizer (United States), University of Pennsylvania
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4220700256